key: cord-0963243-zcphkl1f authors: Chattopadhyay, Pratip K.; Filby, Andrew; Jellison, Evan R.; Ferrari, Guido; Green, Cherie; Cherian, Sindhu; Irish, Jonathan; Litwin, Virginia title: A Cytometrist's Guide to Coordinating and Performing Effective COVID‐19 Research date: 2020-08-16 journal: Cytometry A DOI: 10.1002/cyto.a.24210 sha: ff27f581f34fe985133623dfe33dee4eec643488 doc_id: 963243 cord_uid: zcphkl1f Cytometry is playing a crucial role in addressing the COVID‐19 pandemic. In this commentary ‐ written by a variety of stakeholders in the cytometry, immunology, and infectious disease communities ‐ we review cytometry's role in the COVID‐19 response, and discuss workflow issues critical to planning and executing effective research in this emerging field. We discuss sample procurement and processing, biosafety, technology options, data sharing, and the translation of research findings into clinical environments. This article is protected by copyright. All rights reserved. The world is immersed in a global health challenge on a scale not seen since the 1918 influenza pandemic. COVID-19, caused by the novel SARS-CoV2 virus, has led to nearly 600,000 reported deaths worldwide (as of mid-July 2020) 1 and crippled economies. In the midst of this public health emergency, many researchers and labs have shifted focus toward the study of SARS-CoV2. Presently, many aspects of SARS-CoV2 infection are not fully understood, but there are active research efforts underway studying viral transmission and immune responses, as well as international efforts to develop vaccines and therapies. The human body is made up of 37 trillion cells, which can be grouped in cell populations based on shared phenotypic identities or functional specialization. For the past several decades, cytometrists have been busy dissecting the heterogeneity of these cellular populations 2 , and in the process revealing targets of viral infection, identifying protective immune cells, and characterizing the immune responses that lead to protection or to tissue damage. These are critical needs for the world's COVID-19 response, so understandably cytometry is now playing a crucial role in SARS-Cov2 research. As cytometric technologies are more widely implemented in this new research setting, workflow questions surrounding technology choice, biosafety protocols, quality control, and data sharing are emerging. Moreover, as cytometry is deployed for immune monitoring in vaccine and drug trials, it must be integrated into large studies, some of which are occurring across hospitals taxed by the hefty workloads of their local Accepted Article epidemic, with limited time and resources for planning or preparation; these issues present important challenges as well. In this commentary, we -as stakeholders from various cytometry-associated disciplines -highlight the value of cytometry in the study of COVID-19, and chart a path for how cytometry can be applied and translated successfully to address this grave public health threat ( Figure) . Cytometry, in all its various forms and with all its associated disciplines, has already built the foundation of basic research in COVID-19 immunology 3 . Within months of the declaration of a worldwide pandemic, our community has defined immunologic abnormalities in patients, found associations between immune characteristics and disease severity, and begun to characterize the T-cell response to virus. The quick response of cytometrists to COVID-19 research opportunities is not surprising; the early stages of COVID-19 research have involved the "plug and play" of our existing toolbox into a new disease setting. For a novel disease like COVID-19, the identification and enumeration of different cell types is the foundation upon which further discoveries, and candidate interventions, are built. Early phenotypic analysis of immune cells in COVID patients showed that lymphopenia, and in particular a loss of T-cells in circulation, was a hallmark of Accepted Article This article is protected by copyright. All rights reserved. Using high parameter flow cytometry, one study classified COVID-19 patients into three groups, based on the immunophenotypic state of their T-cell compartment: those patients with CD4+ T-cell activation similar to that observed in acute infections (but only moderate CD8+ T-cell activation), those with highly differentiated CD8+ Tcells, and patients with little indication of immune activation or perturbation. Notably, individuals with the first immunophenotype (CD4+ T-cell activation) tended to have more severe disease 5 . Other studies have identified the loss of suppressive myeloid cells 6 , characterized eosinophils as expanding in the first week, 7 and revealed an increase in plasma-blast B-cells 8 as features of COVID-disease that may be associated with disease severity. Beyond broad phenotypic and functional analysis, cytometry is also used for the critical task of analyzing and evaluating immune responses to viral components. A patient's immune response to specific viral components can be assessed by measuring functional outcomes such as proliferation, cytotoxicity, activation, cytokine secretion, or antibody production upon re-exposure to viral antigens in vitro, or through the direct analysis of cells that bind antigen. The latter is possible using specialized fluorochrometagged reagents called "peptide-MHC multimers," for the analysis of viral antigenspecific T-cells, and antigen trimers for similar analysis of B-cells. These tools will play a central role in the evaluation of vaccine candidates, as they are developed. Most cytometry-related technologies are capable of analyzing both bulk and antigen-specific immune responses with single cell resolution. This article is protected by copyright. All rights reserved. In the first peer-reviewed results from a COVID-19 vaccine-trial, the NIH/Moderna mRNA1273 vaccine 9 was shown to generate SARS-CoV2-specific CD4+ T-cells that expressed the TH1 cytokines IFNg, IL2, and TNF, but not the TH2 cytokines IL4 and IL13 . Notably, past work in mouse models of coronavirus infection showed that immunemediated pathology was associated with TH2-type responses, and TH1-and CD8biased responses in the animal model were associated with better outcomes 10, 11 . Early COVID-19 research has also demonstrated an important role for IL17-producing T-cells in disease 12 , suggesting that anti-IL17 blocking monoclonal antibodies (already available for use in other diseases) might have therapeutic benefit in COVID-19 patients 13 . Studies have also shown that antigen-specific T-cell responses are common in convalescent patients (CD4+ and CD8+ responses against SARS-Cov2 are observed in 100% and 70% of recovered patients), and suggest cross-reactive immunity (since up to 60% of unexposed patients have detectable SARS-CoV2-specific CD4+ T-cells) 14 . These studies only represent a few of the myriad of studies pre-published on bioRxiv and medRxiv to date, many of which demonstrate the clear value of single cell, high parameter flow cytometry for patient-and animal model-oriented COVID-19 research. Flow cytometry also offers a unique ability to purify certain cell subsets -or antigenspecific cells -for downstream analysis using fluorescence-activated cell sorting (FACS). FACS is a critical step for the development of one class of COVID-19 therapeutics, known as passive immunotherapy. In these early phases of the pandemic, passive immunotherapy for COVID-19 has largely involved the infusion of convalescent patient plasma, containing SARS-CoV2 neutralizing antibodies, into severely ill patients. This article is protected by copyright. All rights reserved. Using FACS, it is possible to identify the B-cells making SARS-CoV2 antibodies, sort them into single cell wells, clone them, and then characterize the neutralization ability of antibodies produced by each SARS-CoV2-specific B-cell. The B-cells that produce neutralizing antibodies can thereby be distinguished from those making non-neutralizing antibodies (which do not prevent infection), and sequenced. Using this approach, the sequence of B-cell receptor (i.e., antibody) genes that make neutralizing antibodies are revealed, and these sequences can be transferred to genetically-engineered cell lines for the mass production of neutralizing antibodies, which can then be administered to patients 15 . Mass produced, neutralizing antibody therapeutics (developed using cytometric technology) are the next phase of passive immunotherapies, and represent a potentially important disease treatment strategy with advantages over convalescent plasma. Given the rapid pace of COVID-19 research, and the growing number of laboratories providing immune monitoring for COVID-19 studies, there is an urgent need to harmonize sample collection across sites, and share information about sample stability and marker integrity with sample storage. It is incumbent upon COVID-19 researchers to carefully define procedures and variables in their studies, and to adhere to published standards and guidelines for sample processing and analysis. These steps will ensure that the field moves forward quickly, with robust and meaningful data. In particular, sample quality presents a major challenge in the context of a rapidly unfolding pandemic. It is well known that variables such as collection tube, sample age, and storage conditions can affect cell viability, deplete some cell subsets, alter protein/transcript expression, or the ability to respond in a functional assay 16, 17 . These factors may introduce experimental artifacts that affect data reliability, so understanding the impact of sample quality is critical and must be considered when interpreting data. However, with the rapid pace of SARS-CoV2 research, and the reality of performing research work in the context of a busy clinical setting, extensive evaluation of the impact of preanalytical variables in advance may not be feasible. In these situations, which are not ideal, information from peer reviewed publications, guidelines, and standards, can provide the basis for defining criteria for sample rejection. It is beyond the scope of this communication to make specific recommendations, as the requirements for each individual assay will be different, but immunophenotyping assays provide an example of the need for very specific guidelines. In immunophenotyping, the impact of viability may depend on specimen type, storage conditions, and stability of the cellular population assessed 18 . To further complicate matters, some immunophenotyping assays are performed in a whole blood matrix that includes mild proprietary fixation chemicals, which are designed to extend specimen stability. In this format, viability measurements are not possible. In contrast, immune function tests by ICS or ELISpot assays (which are commonly used to evaluate vaccine efficacy), often use a common threshold of >66% viable cells 19, 20 . In any case, clear standards for sample rejection should be employed not only for settings governed by Good Clinical Lab Practice and regulatory This article is protected by copyright. All rights reserved. guidelines, but should also be seriously considered for non-regulated and non-clinical settings 21, 22 . A unique challenge in COVID-19 research arises from delays in the release of patient samples, while SARS-CoV2 testing is performed. This situation presents a major challenge, since the sample's condition may be questionable by the time it is received by the flow cytometry laboratory. Each investigator must weigh the risk/benefit of testing precious COVID-19 patient samples which may be of suboptimal condition, but if tested, a sample's condition should always be recorded. If a full understanding of the impact of preanalytical variables are not known at the time of testing, investigators are advised to conduct thorough preanalytical evaluation at a later date in order to establish acceptance criteria for sample quality 23 . If this is done, the previously tested samples which would not have met the acceptance criteria can be flagged and removed from the final data set. A second challenge arises from the lymphopenia observed in COVID-19 patients. Immunophenotyping assays must be selected and designed to account for the low number of lymphocytes present in patient peripheral blood. FACS-based purification of rare antigen-specific cells for downstream immunoassays, which would typically be possible from 10 million healthy donor cells, may require two to three times more sample from COVID-19 patients. A key step in experimental design will therefore be to assess the limit of detection and sensitivity of any assay used for COVID-19 research. Similarly, the screening of samples for antigen-specific T-cell populations may be Accepted Article uniquely challenging in COVID-19 patients. Investigators may need to employ highly multiplexed approaches 24 , such as barcoding peptide-MHC Class I multimers with unique combinations of dyes, in order to acquire more information from a single, low yield sample. The challenges described above highlight the critical need for efficiently and clearly sharing methodological information within the COVID-19 scientific community in "realtime" rather than relying on standard peer-reviewed publication timelines. In an effort to meet this need, several journals, including Cytometry Part A, have adopted a process for expedited peer review. In order to have the most impact, it is especially important that the methods sections in the fast-tracked publications are complete and include details of specimen collection and processing. Additionally, professional societies can facilitate the exchange of methodological information, using web-based resources like those proposed at the conclusion of this article. Because SARS-CoV2 is a novel pathogen, most institutions performing COVID-19 research have had to perform risk assessments and develop biosafety strategies unusually quickly. The ability to perform COVID-19 research is highly dependent on this process; in fact, in the United Kingdom, ethical approval for research is not granted without evidence that biosafety protocols are in place. In the United States, local institutional biosafety committees (IBCs) typically perform risk assessments This article is protected by copyright. All rights reserved. In broad terms, these technologies can be grouped into those that measure mRNA transcripts versus protein (or both), or alternatively into technologies that query single cell suspensions versus those that examine tissues. These groupings are helpful in evaluating which technologies are best suited for a particular COVID-19 study. Solely in terms of the sheer volume of data provided, technologies that measure mRNA transcripts are unparalleled. In their most targeted form, these technologies -using for example BD Bioscience's Rhapsody system and Precise Assays -measure four expensive and labor-intensive to deploy for large studies of COVID-patients, (especially for studies that aim to collect samples for every patient admitted to an emergency room, for example). The latter consideration is critical. COVID-19 is a disease with great heterogeneity, in terms of the severity of the disease, the age of patients, and the presence of absence of comorbidities. Powered appropriately, studies will be large and samples must be analyzed quickly, on-demand, as they arrive. Single cell RNA sequencing is not well-suited to such settings. Molecular cytometry, a related technology that replaces antibody fluorescent tags with oligonucleotide tags, overcomes some limitations of unimodal single cell RNA sequencing by directly measuring protein expression. However, the technique requires capture and isolation of single cells from a sample, using a single cell capture device (like the 10X Chromium or BD Rhapsody systems). These capture devices are limited to the capture of no more than 20,000 cells per capture, which is very low for immunophenotyping rare cell populations (but certainly sufficient to study immune landscapes); the analysis of more cells is certainly possible, but the need for additional materials increases cost and labor. In contrast, single cell analysis of cellular proteins typically provides a good combination of throughput, cost, and data content 30 . Technologies based on the measurement of cellular proteins include high parameter flow cytometry, spectral flow cytometry, mass cytometry, imaging flow cytometry, imaging mass cytometry, and CODEX. These technologies all use antibodies to mark cellular proteins; the antibodies carry different tags (e.g., fluorescent dyes, elemental isotopes) based on the method of detection used for each platform. In particular, high parameter flow, mass, and spectral cytometry can Accepted Article support the analysis of 1 million cells or more from each cell sample, and patient samples can be analyzed on automated platforms. The samples used for these studies are often stable for longer than those used for mRNA-based studies, since generally proteins are less labile than mRNA transcripts, and less affected by changes in cellular environment. The primary keys to success when using these technologies are authentication/titration of antibodies 31 and standardization of instrumentation across sites 32 (which often presents a considerable challenge). A major limitation of these technologies is their relative complexity. For flow and spectral cytometry, the design of antibody panels is critical and time consuming; while for mass cytometry, instrument calibration, as well as reagent production and qualification can require considerable effort. In these regards, sharing of antibody panels across the COVID-19 cytometry community may be very helpful 33 , as would the creation of local "libraries" of antibody reagents. Cytometry technologies may also be grouped by the matrix in which the measurements are made. Technologies that measure cells in suspension include: flow, mass, spectral, imaging flow, and molecular cytometry, along with IsoLight's single cell cytokine secretion platform and single cell RNA sequencing. Technologies that measure cells within tissue include imaging mass cytometry, CODEX, and spatial transcriptomics. In the most general terms, tissue-based technologies will have little value for the study of patients with asymptomatic or mild disease, because these conditions are not accompanied by tissue pathology. Moreover, ethical approval is not likely to be granted to sample a lymph node or lung tissue in relatively healthy individuals. Blood is much Accepted Article more accessible and available for these patients, so studies that involve healthy or early stage individuals will likely use technologies that measure cells in suspension. Yet it is important to remember that severe COVID-19 disease typically manifests in lung tissue, so deploying tissue-based technologies is likely to provide the biggest experimental value at a lower cost in understanding severe disease. Where tissue is not available, but interventional pulmonologists are accessible, an alternate approach for studying tissue-resident immune cells is to perform bronchoalveolar lavages (BAL), which "wash" cells out of lungs for collection. When deciding what approach is best for analyzing COVID19 samples, it is important to appreciate the inverse correlation between parameters and throughput. Fluorescence flow cytometry is still by far the most cost-effective approach to single cell analysis, but it is limited by parameter space. As such, lower parameter flow cytometry may be seen as a technology used to confirm findings. At the other end of the scale, molecular cytometry provides the parameter space to perform very deep and comprehensive analysis of single cells. It is more likely to discover new and unappreciated heterogeneity, but is generally not well suited to large studies, because cost considerations preclude scalability. The reality is that a combinatorial approach of very high parameter/low throughput "discovery" and focused, lower parameter/higher throughput confirmation will be the best approach. Studies will likely use mostly suspension cytometry technologies, because successful translation into a clinical setting will require more standardized approaches in which the key questions/parameters are distilled down to what is minimally required to call cell phenotype or function. Particular cytometry technologies allow unique applications that could be of great value to COVID-19 projects. In a previous section, we described how fluorescence flow cytometry offers live cell sorting, which plays a key role in the development of passive immunotherapy using neutralizing antibodies. Similarly, immunoassays that characterize cell functions like proliferation are uniquely performed in fluorescence flow cytometry (and likely spectral flow cytometry) settings. The beauty of these approaches is that other measurements can be multiplexed in a single step providing a deep, simultaneous characterization of cell phenotype and function. As described above, from a discovery perspective, we expect that molecular cytometry technology, with its unmatched information content, will yield great insight into SARS-CoV2 pathogenesis. Using this technology, it is also possible to examine the clonality of T-cells and B-cells in COVID-19 patient samples, by sequencing T-cell receptor and immunoglobulin genes, respectively. This approach represents a powerful means to map the immune response to COVID-19 antigens, a key element of vaccine studies. Finally, imaging flow cytometry technologies capture not only the average fluorescence of a marker bound to a cell, but also the specific location of that signal on the cell. Currently available systems can measure up to 12 parameters per cell, however since the output is based on digital imagery, it is possible to derive a near limitless number of parameters that often require advanced analysis approaches such as deep learning to extract meaning. In any case, this technology will likely provide information about where on the cell surface SARS-CoV2 particles are bound. This article is protected by copyright. All rights reserved. The efficient response of the scientific community to this pandemic will require the sharing of not only knowledge, but also the data from which that knowledge is derived. This is especially important for data arising from technologies with high information content, like multidimensional cytometry. With the rapid pace of COVID-19 research, it is unlikely that a laboratory generating a dataset can completely mine their own data before publication, so opportunities to further extract knowledge are missed when data is not freely distributed in the community. A fine example of both the use and distribution of publicly available datasets is illustrated by the work of a Belgian research group 34 , who provided an immune atlas of BAL specimens from patients with mild COVID-, severe COVID-, or non-COVID-related pneumonia. Data from non-COVID-related pneumonia was re-analyzed from their previous study, providing important context for their COVID-related findings. Similarly, a dataset comparing healthy children and those with Kawasaki syndrome (a multi-system inflammatory disease) to the COVID-related manifestation of this syndrome has recently been posted to medRxiv 35 . This dataset will be remarkably valuable because these syndromes are quite rare, and the COVIDrelated manifestation was only very recently reported. Publicly available flow cytometry data from COVID-19 research is also being used in new and unique ways. A key challenge in flow cytometry centers around the discrimination of cells expressing a marker versus those that lack expression ("gating"). Gating can vary significantly between data analysts, and automated gating algorithms do not always capture the gates that human analysts would have set. This discordance Accepted Article can have downstream effects, making it harder to interpret comparisons between patient groups because some cell populations are over-or under-represented in the dataset. This challenge may be solved by crowd-sourcing gating across a wide range of analysts, as a new project is currently testing 36 . This project "gamifies" publicly available flow cytometry datasets, allowing anyone -including the lay public -the opportunity to set their own gates as part of a web-based video game. The objective of translational and clinical science has always been to accelerate the bench-to-bedside progress. This objective has never been more urgently needed as during the COVID-19 pandemic. Much of the effort in SARS-CoV2/COVID-19 research is directed towards the identification of biomarkers that predict control or progression of disease, or assess novel therapeutic agents and strategies. Promising findings will need to be evaluated in clinical laboratories, for their potential to be incorporated into clinical care. In addition, there will be a strong push to develop the most interesting findings into diagnostic tests. These efforts will require laboratories to meet regulatory guidelines, which may be reviewed more quickly by regulators, but are unlikely to be substantially loosened or ignored. As such, the generation of high quality, welldocumented, quality-controlled data from clinical laboratories and manufacturers is paramount. Data to meet regulatory requirements, and indeed the antibody panels themselves, are likely to be easily ported to the SARS-CoV2 settings by connecting the right researchers. The key elements for successful translational and clinical science involve standardization 42 , harmonization, and method validation. As we are still in the early days of SARS-CoV2 research, progress in standardization and harmonization is critically needed. For example, descriptions of antigen-specific T-cell responses to SARS-CoV2 This article is protected by copyright. All rights reserved. have differed across studies because of the varying coverage of peptide pools. An important step forward will be to standardize reagents in the field, particularly peptide pools. Similarly, to enroll the number of patients required for studies of COVID-19 pathogenesis or vaccine immunogenicity, multiple centers will be required. To compare results across multiple trial sites in a reliable and structured manner, external quality assurance programs, like those implemented for HIV/AIDS vaccine trials will be needed 43 . Facilitating multi-center translational studies, antibody reagent mixtures dried in single test tubes can be produced on demand by major companies. Apart from driving assay standardization at the reagent level, the use of dried/lyophilized antibody panels for flow cytometry will also help in simplifying the experimental workflow and relieving the burden on hospital and research staff conducting critical research while dealing with a local epidemic. In sum, efforts to harmonize work from multiple SARS-CoV2 laboratories will greatly benefit the public health response to COVID-19. Professional societies that support cytometry can play an important role in the scientific response to COVID-19. This May, the International Society for the Advancement of Accepted Article work performed in research settings will need to be translated rapidly into clinical laboratory settings. Given the magnitude and severity of the pandemic, people across diverse disciplinesin research, industry, and clinical laboratorieshave shifted their focus to SARS-CoV2. The breadth and depth of science represented will surely benefit society, but the greatest benefits can only be realized if expertise is efficiently shared amongst scientists. Already, as addressed here, there are common questions emerging about how to plan for SARS-CoV2 research, including issues of biosafety, sample procurement, experimental design, and data analysis. The ISAC COVID-19 Workgroup will assist in these areas, providing a centralized source for biosafety guidelines, a forum to discuss experimental design, a networking directory to establish collaborations, and a connection to data repositories and analysis algorithms. In today's climate, with the unfortunate politicization of science, it is more important than ever that laboratories generate high quality, reproducible data with traceable, calibrated measurements; ISAC's COVID-19 Workgroup will help shape that process. Accepted Article An interactive web-based dashboard to track COVID-19 in real time Flow cytometry strikes gold Immunology of COVID-19: Current State of the Science Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Suppressive myeloid cells are a hallmark of severe COVID-19 Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. medRxiv Comprehensive mapping of immune perturbations associated with severe COVID-19 An mRNA vaccine against SARS-CoV2 -Preliminary Report Rapid COVID-19 vaccine development SARS-CoV2 mRNA vaccine development enabled by prototype pathogen preparedness Marked T-cell activation, senescnece, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia COVID-19: a case for inhibiting IL-17? Selective and cross-reactive SARS-CoV-2 T-cell epitopes in unexposed humans Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV2 spike protein Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS-part II-preanalytical issues Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays Impact of blood storage and sample handling on quality of high dimensional flow cytometric data in multicenter clinical research Moving to HIV Type 1 Vaccine Efficacy Trials: Defining T-cell Responses As Potential Correlates of Immunity The External Quality Assurance Oversight Laboratory (EQAPOL) Proficiency Program for IFN-gamme Enzyme-Linked ImmunoSpot Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells, 2 th ed. CLSI document H43 Enumeration of Immunologically Defined Cell Populations by Flow Cytometry, 2 th ed. CLSI document H42. Wayne, PA: Clinical Laboratory Standards Institute Recommendations for the Evaluation of Specimen Stability for Flow Cytometric Testing During Drug Development Profound CD8 T-cell responses toward the SARS-CoV2 ORF1ab in COVID-19 patients Molecular detection of SARS-CoV2 infection in FFPE samples and histopathologic findings in fatal SARS-COV2 cases Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series International Society for the Advancement of Cytometry Cell Sorter Biosafety Standards Handling and processing of blood specimens from patients with COVID-19 for safe studies on cell phenotype and cytokine storm Guidelines for the use of flow cytometry and cell sorting in immunological studies A deadly dance: the choreography of host-pathogen interactions, as revealed by single-cell technologies Relevance of antibody validation for flow cytometry How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers Publication of optimized multicolor immunofluorescence panels Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages The immunology of multisystem inflammatory syndrome in children with COVID-19 We thank the other members of ISAC's COVID- 19 This article is protected by copyright. All rights reserved. The authors have no conflicts of interest to report. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.